Related trials
BASKET-PROVE (SES), 2010 - sirolimus eluting stent vs bare-metal stent
GISSOC II, 2010 - sirolimus eluting stent vs bare-metal stent
RESOLUTE All comers, 2010 - zotarolimus eluting stent vs everolimus eluting stent
SORT-OUT-3, 2010 - zotarolimus eluting stent vs sirolimus eluting stent
SPIRIT IV, 2010 - everolimus eluting stent vs paclitaxel eluting stent
BASKET-PROVE (EES), 2010 - everolimus eluting stent vs bare-metal stent
ISAR TEST 2 (vs ZES), 2009 - dual sirolimus, probucol eluting stent vs zotarolimus eluting stent
Thiele, 2009 - sirolimus ES vs MIDCAB
ENDEAVOR IV, 2009 - zotarolimus eluting stent vs paclitaxel eluting stent
ZEST AMI (vs PES), 2009 - zotarolimus eluting stent vs paclitaxel eluting stent
COMPARE, 2009 - everolimus eluting stent vs paclitaxel eluting stent
ISAR TEST 2 (vs SES), 2009 - dual sirolimus, probucol eluting stent vs sirolimus eluting stent
ZEST (vs PES), 2009 - zotarolimus eluting stent vs paclitaxel eluting stent
ZEST (vs SES), 2009 - zotarolimus eluting stent vs sirolimus eluting stent
ISAR TEST 3 (BP), 2009 - sirolimus biodegradable polymer vs sirolimus eluting stent
ISAR-TEST-4 (biodegradable polymer), 2009 - sirolimus biodegradable polymer vs sirolimus eluting stent
GENIUS-STEMI, 2009 - Genous stent vs bare-metal stent
SYNTAX, 2009 - paclitaxel eluting stent vs CABG
PASEO, 2009 - drug-eluting stents vs bare-metal stent
ISAR TEST 3 (PF), 2009 - polymer free sirolimus stent vs sirolimus eluting stent
DEBATER (SES vs BMS), 2009 - sirolimus eluting stent vs bare-metal stent
ISAR-LEFT-MAIN, 2009 - sirolimus eluting stent vs paclitaxel eluting stent
ZEST AMI (vs SES), 2009 - zotarolimus eluting stent vs sirolimus eluting stent
SORT OUT II, 2008 - sirolimus eluting stent vs paclitaxel eluting stent
DES-DIABETES, 2008 - sirolimus eluting stent vs paclitaxel eluting stent
See also:
All coronary artery disease clinical trials
All clinical trials of Drug eluting stent
All clinical trials of Genous stent
|
|
Treatments
Studied treatment |
endothelial progenitor cell capture stent
|
Control treatment |
cobalt chromium stent
|
Concomittant treatment |
dual antiplatelet therapy for 30 days |
Patients
Patients |
patients with ST-elevation myocardial infarction |
Baseline characteristics |
age |
57 y |
diabetes (%) |
29% |
Female (%) |
21% |
STEMI |
100% |
|
Method and design
Randomized effectives |
50 / 50 (studied vs. control) |
Design |
Parallel groups |
Blinding |
NA |
Follow-up duration |
6 months |
Primary endpoint |
MACE |
Results
Endpoint
Studied treat. n/N
Control treat. n/N
Graph
RR [95% CI]
MACE
MI (fatal and non fatal)
target lesion revascularisation
4y stent thrombosis (ARC)
3 / 50
0 / 50
classic
13,00 [0,23;745,45]
0
2
1.0
Relative risks
|
Endpoint |
Events (%) |
Relative Risk |
95% CI |
Endpoint definition in the trial |
Ref |
Studied treat. |
Control treat. |
4y stent thrombosis (ARC)
|
3 / 50 (6,0%) |
0 / 50 (1,0%) |
6,00 |
[0,31;116,74] |
|
|
The primary endpoint (if exists) appears in blod characters
|
Reference(s) used for data extraction:
|
Endpoint |
studied treat. |
control treat. |
mean diff |
Absolute risk reduction
|
Endpoint |
Events rate |
Absolute risk reduction (ARR) |
Studied treat. |
Control treat. |
Meta-analysis of all similar trials:
Drug eluting stent in coronary artery disease for acute myocardial infarction
Drug eluting stent in coronary artery disease for all type of patients
Reference(s)
-
Cervinka .
A Randomized Comparison of Genous Stent Versus Chromium-Cobalt Stent for Treatment of ST-Elevation Myocardial Infarction: A 6-Month Clinical, Angiographic, and IVUS Follow-up: GENIUS-STEMI trial.
ACC.09/i2, Orlando, FL, March 2009
Pubmed
|
Hubmed
| Fulltext
|